HGSI completes two Phase IIa trials

Human Genome Sciences (HGSI) completed enrollment of a total of 100 patients in two U.S. Phase IIa trials of mirostipen myeloid progenitor inhibitory factor (MPIF) to treat chemotherapy-induced neutro...